102 related articles for article (PubMed ID: 2292763)
21. Transdermal timolol delivery from a Pluronic gel.
Stamatialis DF; Rolevink HH; Koops GH
J Control Release; 2006 Nov; 116(2):e53-5. PubMed ID: 17718968
[No Abstract] [Full Text] [Related]
22. Water-activated, pH-controlled patch in transdermal administration of timolol. II. Drug absorption and skin irritation.
Sutinen R; Paronen P; Saano V; Urtti A
Eur J Pharm Sci; 2000 Jul; 11(1):25-31. PubMed ID: 10913750
[TBL] [Abstract][Full Text] [Related]
23. The kinetics of timolol in the rabbit lens: implications for ocular drug delivery.
Ahmed I; Francoeur ML; Thombre AG; Patton TF
Pharm Res; 1989 Sep; 6(9):772-8. PubMed ID: 2813274
[TBL] [Abstract][Full Text] [Related]
24. Skin irritation induced by topically applied timolol.
Kubota K; Koyama E; Yasuda K
Br J Clin Pharmacol; 1991 Apr; 31(4):471-5. PubMed ID: 2049257
[TBL] [Abstract][Full Text] [Related]
25. Toxicokinetics and metabolism of N-[(14)C]N-methyl-2-pyrrolidone in male Sprague-Dawley rats: in vivo and in vitro percutaneous absorption.
Payan JP; Boudry I; Beydon D; Fabry JP; Grandclaude MC; Ferrari E; André JC
Drug Metab Dispos; 2003 May; 31(5):659-69. PubMed ID: 12695356
[TBL] [Abstract][Full Text] [Related]
26. Improvement of the ocular bioavailability of timolol by sorbic acid.
Higashiyama M; Inada K; Ohtori A; Tojo K
Int J Pharm; 2004 Mar; 272(1-2):91-8. PubMed ID: 15019072
[TBL] [Abstract][Full Text] [Related]
27. Analysis of in vitro skin permeation of 22-oxacalcitriol having a complicated metabolic pathway.
Yamaguchi K; Mitsui T; Yamamoto T; Shiokawa R; Nomiyama Y; Ohishi N; Aso Y; Sugibayashi K
Pharm Res; 2006 Apr; 23(4):680-8. PubMed ID: 16550468
[TBL] [Abstract][Full Text] [Related]
28. [The bioavailability of transdermal therapeutic system of timolol].
Ji XF; Ping QN; Liu GJ; Yu ST
Yao Xue Xue Bao; 1993; 28(8):609-13. PubMed ID: 8285070
[TBL] [Abstract][Full Text] [Related]
29. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.
Aboofazeli R; Zia H; Needham TE
Drug Deliv; 2002; 9(4):239-47. PubMed ID: 12511202
[TBL] [Abstract][Full Text] [Related]
30. Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment.
Anigbogu AN; Williams AC; Barry BW
J Pharm Pharmacol; 1996 Apr; 48(4):357-66. PubMed ID: 8794983
[TBL] [Abstract][Full Text] [Related]
31. Prediction of steady-state skin permeabilities of polar and nonpolar permeants across excised pig skin based on measurements of transient diffusion: characterization of hydration effects on the skin porous pathway.
Tang H; Blankschtein D; Langer R
J Pharm Sci; 2002 Aug; 91(8):1891-907. PubMed ID: 12115816
[TBL] [Abstract][Full Text] [Related]
32. Initial evaluation of transdermal timolol: serum concentrations and beta-blockade.
Vlasses PH; Ribeiro LG; Rotmensch HH; Bondi JV; Loper AE; Hichens M; Dunlay MC; Ferguson RK
J Cardiovasc Pharmacol; 1985; 7(2):245-50. PubMed ID: 2581075
[TBL] [Abstract][Full Text] [Related]
33. Effect of Mild Hyperthermia on Transdermal Absorption of Nicotine from Patches.
Panda A; Sharma PK; Narasimha Murthy S
AAPS PharmSciTech; 2019 Jan; 20(2):77. PubMed ID: 30635802
[TBL] [Abstract][Full Text] [Related]
34. Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects.
Kaila T; Huupponen R; Salminen L
J Ocul Pharmacol; 1986; 2(4):365-9. PubMed ID: 3503120
[TBL] [Abstract][Full Text] [Related]
35. Bioadhesive dosage form for peroral administration of timolol base.
Deasy PB; O'Neill CT
Pharm Acta Helv; 1989; 64(8):231-5. PubMed ID: 2780757
[TBL] [Abstract][Full Text] [Related]
36. Diffusion modeling of percutaneous absorption kinetics: 2. Finite vehicle volume and solvent deposited solids.
Anissimov YG; Roberts MS
J Pharm Sci; 2001 Apr; 90(4):504-20. PubMed ID: 11170040
[TBL] [Abstract][Full Text] [Related]
37. Effects of low-frequency ultrasound on the transdermal permeation of mannitol: comparative studies with in vivo and in vitro skin.
Tang H; Blankschtein D; Langer R
J Pharm Sci; 2002 Aug; 91(8):1776-94. PubMed ID: 12115805
[TBL] [Abstract][Full Text] [Related]
38. Significance of viable skin layers in percutaneous permeation and its implication in mathematical models: theoretical consideration based on parameters for betamethasone 17-valerate.
Kubota K; Maibach HI
J Pharm Sci; 1994 Sep; 83(9):1300-6. PubMed ID: 7830247
[TBL] [Abstract][Full Text] [Related]
39. Percutaneous absorption of Mexoryl SX in human volunteers: comparison with in vitro data.
Benech-Kieffer F; Meuling WJ; Leclerc C; Roza L; Leclaire J; Nohynek G
Skin Pharmacol Appl Skin Physiol; 2003; 16(6):343-55. PubMed ID: 14528058
[TBL] [Abstract][Full Text] [Related]
40. Reconstructed skin equivalents for assessing percutaneous drug absorption from pharmaceutical formulations.
Zghoul N; Fuchs R; Lehr CM; Schaefer UF
ALTEX; 2001; 18(2):103-6. PubMed ID: 11378682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
